Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation

Bone Marrow Transplantation
K J ThomsonS Mackinnon

Abstract

This study compares outcome of reduced-intensity conditioned transplant (RIT) with outcome of conventional non-transplant therapy in patients with Hodgkin's lymphoma relapsing following autograft. There were 72 patients in two groups who had relapsed, and received salvage therapy with chemotherapy+/-radiotherapy. One group (n=38) then underwent alemtuzumab-containing RIT. The second group-historical controls (n=34), relapsing before the advent of RIT-had no further high-dose therapy. This group was required to respond to salvage therapy and live for over 12 months post-relapse, demonstrating potential eligibility for RIT, had this been available. Overall survival (OS) from diagnosis was superior following RIT (48% at 10 years versus 15%; P=0.0014), as was survival from autograft (65% at 5 years versus 15%; P< or =0.0001). For the RIT group, OS at 5 years from allograft was 51%, and in chemoresponsive patients was 58%, with current progression-free survival of 42%. Responses were seen in 8 of 15 patients receiving donor lymphocyte infusions (DLI) for relapse/progression, with durable remission in five patients at median follow-up from DLI of 45 months (28-55). These data demonstrate the potential efficacy of RIT in heavily pre-t...Continue Reading

References

Dec 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J E AndersonJ E Sanders
Feb 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J L GajewskiM M Horowitz
Apr 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N MilpiedA H Goldstone
Dec 4, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G AkpekR J Jones

❮ Previous
Next ❯

Citations

Aug 24, 2010·Current Hematologic Malignancy Reports·Rachel B SalitSteven Z Pavletic
Jul 9, 2009·Bone Marrow Transplantation·P LjungmanUNKNOWN European Group for Blood and Marrow Transplantation
May 29, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C MartínezUNKNOWN Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (EBMT) and the Gruppo Italiano Trapianto d
Oct 20, 2012·Current Opinion in Oncology·Anna SuredaUNKNOWN Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
Jan 1, 2011·Revista brasileira de hematologia e hemoterapia·Poliana PatahMarcos de Lima
Apr 23, 2014·Current Treatment Options in Oncology·Anna SuredaUNKNOWN Lymphoma Working Party of the European Group for Stem Cell Transplantation
Jun 21, 2011·Advances in Hematology·S E Richardson, C McNamara
Jun 1, 2009·Expert Review of Hematology·David Sibon, Pauline Brice
Apr 17, 2013·Expert Opinion on Biological Therapy·Tiziana MoscatoMassimo Martino
Jun 28, 2011·Expert Opinion on Biological Therapy·Xavier Poiré, Koen van Besien
Nov 30, 2013·Hematology/oncology Clinics of North America·Catherine Diefenbach, Ranjana Advani
Nov 30, 2013·Hematology/oncology Clinics of North America·Mark Hertzberg
Oct 9, 2013·Experimental Hematology·Adam JonaArpad Illés
Mar 24, 2010·Pediatric Clinics of North America·David BarrettStephan A Grupp
Jan 21, 2016·Journal of Immunology Research·Roberta FedeleFortunato Morabito
Nov 11, 2014·American Journal of Hematology·Shinichi KakoUNKNOWN Adult Lymphoma Working Group of the Japanese Society for Hematopoietic Cell Transplantation
Aug 20, 2008·British Journal of Haematology·Karl S PeggsAnna Sureda
Dec 16, 2010·British Journal of Haematology·Paolo CorradiniLucia Farina
Jun 9, 2010·The Journal of Pathology·Donatella AldinucciAntonino Carbone
Nov 13, 2015·European Journal of Haematology·Barbara Jezeršek Novaković
Oct 15, 2013·British Journal of Haematology·Graham P CollinsKarl S Peggs
Mar 17, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Miguel-Angel PeralesPaul A Carpenter
Oct 4, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Panayotis KaloyannidisAchilles Anagnostopoulos
Mar 17, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Luca CastagnaArmando Santoro
Jan 27, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Claudio G BrunsteinJohn E Wagner

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.